Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
First non-immunosuppressive therapy for the treatment of IgA Nephropathy (IgAN) approved in Europe
Conditional marketing authorization is based on statistically significant and clinically meaningful results from the phase-III PROTECT trial
Posted In: TVTX